Delayed Bone Age and Osteoprotegerin Levels in Pediatric Celiac Disease: A Three-Year Case-Control Study

Ruzha Pancheva1, Yoana Dyankova2, Niya Rasheva2

  • 1Department of Hygiene and Epidemiology, Faculty of Public Health, Prof. Dr. Paraskev Stoyanov Medical University, 9000 Varna, Bulgaria.

Nutrients
|July 30, 2025
PubMed

Insights

Osteoprotegerin (OPG) levels reflect disease activity and growth delay in pediatric celiac disease (CD). However, OPG is not a reliable standalone biomarker for predicting delayed bone age in these children.

Area of Science:

  • Pediatric Endocrinology
  • Gastroenterology
  • Bone Metabolism

Background:

  • Celiac disease (CD) negatively impacts bone development in children due to inflammation and malabsorption.
  • Osteoprotegerin (OPG), a key regulator of bone remodeling, is a potential biomarker for bone health and inflammation.
  • The clinical utility of OPG in pediatric CD requires further investigation.

Purpose of the Study:

  • To assess the relationship between OPG levels, growth parameters, and bone age delay in pediatric CD patients.
  • To evaluate OPG as a potential biomarker for bone health and disease activity in children with CD.

Main Methods:

  • A three-year case-control study involving 146 children (25 newly diagnosed CD, 54 established CD on gluten-free diet, 67 controls).
  • Measurements included OPG, osteocalcin, anthropometrics, and radiological bone age assessment.
  • Statistical analyses comprised ANOVA, Spearman's correlations, and logistic regression.

Main Results:

  • Elevated OPG levels were observed in newly diagnosed CD patients, with a slight, non-significant decrease after gluten-free diet adherence.
  • OPG levels showed negative correlations with age and height in CD patients and controls.
  • OPG did not significantly predict delayed bone age, though a trend was noted in established CD patients.

Conclusions:

  • OPG levels correlate with disease activity and growth delay in pediatric CD.
  • OPG is not a suitable standalone biomarker for predicting skeletal maturation or delayed bone age.
  • Integrated biomarker panels are recommended for comprehensive bone health monitoring in children with CD.